Ipca Laboratories
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Ipca Laboratories is strategically transitioning towards a value-driven business model, emphasizing higher-margin segments and leveraging its R&D capabilities to enhance its product offerings in regulated markets. Management's guidance for FY27 indicates a consolidated revenue growth of 12-13% and an EBITDA margin improvement to 22-22.3%, driven by strong domestic performance and a robust pipeline of new product launches. However, the company faces challenges from rising raw material and freight costs, which are expected to increase by 10-12% and 25%, respectively. Despite these pressures, management is optimistic about offsetting costs through strategic price increases and operational efficiencies. The overall financial outlook remains stable, with revenue growth expected to align with historical performance and margins projected to remain stable. The Indian pharmaceutical sector's favorable conditions, including improving pricing power and a strong export market, further support Ipca's growth trajectory. Over the next 12-24 months, key opportunities include successful product launches and market share gains, while watchpoints include execution risks related to regulatory compliance and input cost pressures
Why We Like This Stock
- Management's guidance for FY27 indicates a consolidated revenue growth of 12-13% and EBITDA margin improvement to 22-22.3%
- The company's strong R&D capabilities and a robust pipeline of new product launches position it well for future growth
- Favorable industry conditions, including improving pricing power and a strong export market, support revenue growth
Things To Watch Out For
- Rising raw material costs are expected to increase by 10-12%, impacting margins
- Elevated freight costs, projected to rise by 25%, may challenge profitability
- Execution risks related to regulatory compliance could hinder operational performance
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 7,662 | 8,897 | 9,646 | 10,684 | 11,872 |
| Profit Before Tax (Cr.) | 917 | 1,304 | 1,659 | 2,270 | 2,373 |
| PBT Margin | 12.0% | 14.7% | 1719.9% | 21.2% | 20.0% |
| Net Profit (Cr.) | 569 | 872 | 1,208 | 1,669 | 1,683 |
| Earnings Per Share | 23.4 | 32.5 | 45.9 | 63.4 | 66.3 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Emkay Global | ▲ Buy | 1,800 | 02-Jun-2026 |
| Motilal Oswal | ▲ Buy | 1,730 | 02-Jun-2026 |
| Nomura | ▲ Buy | 1,725 | 01-Jun-2026 |
| Prabhudas Liladhar | ▲ Buy | 2,000 | 17-Aug-2026 |
Company Overview
Show Company Profile
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.